Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide
Background: The highly vascular nature of renal carcinoma cells suggests that inhibition of angiogenesis may be beneficial in this disease. Thalidomide has been described as inhibitor of the fibroblast growth factor (FGF) and the vascular endothelial growth factor (VEGF). Therefore and in considerat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | deu |
| Published: |
German Medical Science GMS Publishing House
2009-06-01
|
| Series: | GMS German Medical Science |
| Subjects: | |
| Online Access: | http://www.egms.de/en/gms/2009-7/000063.shtml |